报价延迟最少15分钟:2025/09/16 15:38 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.095 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.42/--
|
|
企业价值
2.48B
|
| 资产负债 |
|
每股账面净值
-11.45
|
| 现金流量 |
|
现金流量率
0.15
|
| 损益表 |
|
收益
1.12B
|
|
每股收益
19.04
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/16 15:38 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safetydevices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States. |
